lenalidomide has been researched along with trametinib in 3 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (trametinib) | Trials (trametinib) | Recent Studies (post-2010) (trametinib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 940 | 134 | 926 |
| Protein | Taxonomy | lenalidomide (IC50) | trametinib (IC50) |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.0043 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.0011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Chan, PP; Chatfield, KC; Dahl, NA; Foreman, NK; Hemenway, MS; Mirsky, DM; Sabus, A; White, CJ | 1 |
1 review(s) available for lenalidomide and trametinib
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
2 other study(ies) available for lenalidomide and trametinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Lenalidomide; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones | 2023 |